The verdict
Our read at a glance.
Whether an early-generation SARM with animal muscle and bone data has any demonstrated benefit in people.
- The signal
- The animal work is real and consistent. Andarine restored muscle strength and body composition in castrated rats and improved bone in osteopenic female rats, which is what made the arylpropionamide series interesting in the first place. Its pharmacokinetics were characterised in animals in 2004. After that the trail goes cold for human efficacy: the compound is now studied mainly as a starting point in cancer pharmacology, where it has been examined for anti-proliferative activity in pancreatic, hepatocellular and glioblastoma cell models, and as an analyte in anti-doping laboratories, where its urinary metabolites have been characterised specifically so that use can be detected.
- The unknown
- Whether any of the animal muscle and bone findings translate to humans at all. There is no published, controlled human efficacy trial for this compound, so the entire benefit case rests on rodents.
- Our read
- A compound whose reputation runs entirely ahead of its evidence. Rodent data, no human efficacy trial, a side effect people know about from forums rather than from a study, and a modern literature built around catching it in urine. If you are choosing between SARMs on the basis of evidence, this is the one with the least.
The mechanism
How it works.
Andarine is an arylpropionamide, one of the first non-steroidal selective androgen receptor modulators to come out of that chemical series. It binds the androgen receptor as a partial agonist, activating it strongly enough in muscle and bone to produce anabolic effects in animals while acting more weakly in tissues like the prostate. Partial agonism is also why it can behave as a competitor at the receptor, blunting the effect of the body's own androgens in some tissues. The visual complaints people report are usually attributed to the compound or its metabolites interacting with retinal pigment, which would fit an effect that appears at higher doses and resolves after stopping, but that mechanism has not been established in a controlled human study.
Safety & regulatory boundary
The consequential part.
Not approved anywhere for any indication and not a lawful dietary supplement ingredient. FDA has warned consumers about bodybuilding products containing SARMs. Prohibited in sport at all times as an anabolic agent, and confirmed in real doping control samples. Product sold under this name is a research chemical of unverified identity. The commonly reported visual effect is a documented user-level phenomenon rather than something characterised in a controlled human trial, which is itself a comment on how thin the human record is.
What's next
What we're watching.
Any controlled human study, and whether the oncology repurposing work produces anything that changes the read on the parent molecule.
Context
Why this is discussed.
It is still sold widely as a cutting compound, and it is one of the few SARMs with a distinctive, frequently reported subjective effect people trade stories about: a yellow tint to vision and trouble adapting to the dark.
The evidence base
9 cited references.
Indexed literature (PubMed)9
Thevis M et al. · Drug Test Anal · 2009
Bölük A et al. · Biochem Biophys Res Commun · 2023
Thevis M et al. · Rapid Commun Mass Spectrom · 2010
Starcevic B et al. · Drug Test Anal · 2013
Yavuz M et al. · Toxicol Appl Pharmacol · 2024
Kearbey JD et al. · Xenobiotica · 2004
Kearbey JD et al. · Pharm Res · 2009
Yavuz M et al. · Gene · 2023
Gao W et al. · Endocrinology · 2005
Keep reading